Sweden's Sedana Medical Q1 sales fall 7% due to lower ICU patient volumes

Sedana Medical AB (publ)

23/04/2026 06:12

Overview

Sweden medtech-pharma firm's Q1 sales fell 7% yr/yr due to lower ICU patient volumes

Company posted positive EBITDA for Q1, reflecting improved operational efficiency

Net loss narrowed, mainly due to absence of negative currency effects seen last year

Outlook

Sedana Medical expects continued growth in distributor markets during 2026

Company remains on track to submit US FDA New Drug Application in mid-2026

Company says seasonal ICU occupancy variations will continue to influence business

Result Drivers

LOWER ICU PATIENT VOLUMES - Co said sales decline was mainly due to fewer sedated ICU patients compared to last year's strong flu season

OPERATIONAL EFFICIENCY - Co attributed positive EBITDA to structural improvements, including streamlining headquarters and reallocating resources to profitable markets

REGIONAL VARIATION - Co noted Germany saw a 15% sales decline due to lower ICU admissions, while Spain grew despite doctor strikes and distributor markets delivered 23% growth

Company press release: ID:nMFN2hGpF7

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Sales
SEK 53.40 mln
Q1 Adjusted EPS
-SEK 0.04
Q1 Net Income
-SEK 3.70 mln
Q1 Cash Flow From Operating Activities
SEK 2.70 mln
Q1 EBITDA
SEK 1.80 mln
Q1 EBIT Margin
-11.00%


Analyst Coverage

The one available analyst rating on the shares is "buy"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)